MCC950 sodium for NLRP3 research

MCC950 sodium, also known as CRID3 sodium salt, is a selective small-molecule tool for testing whether NLRP3 inflammasome activity contributes to an inflammatory phenotype. APExBIO supplies this reagent for workflows spanning macrophages, human peripheral blood mononuclear cells, endotoxemia, and autoimmune disease models. Unlike broad anti-inflammatory interventions, it can help separate NLRP3-dependent interleukin-1β (IL-1β) release from upstream inflammatory priming and from TNF-α secretion.

Setup and principle overview

The central experimental question is not simply whether a stimulus increases inflammation, but which part of the response depends on NLRP3. Lipopolysaccharide (LPS), for example, can provide a strong priming signal through TLR4 while also engaging intracellular pathways associated with noncanonical inflammasome activation. MCC950 sodium is useful after this distinction has been built into the study design: it inhibits canonical and noncanonical NLRP3 activation, but it does not serve as a universal inflammasome inhibitor.

In murine bone marrow-derived macrophages (BMDMs), the reported IC₅₀ is 7.5 nM, with comparable potency and selectivity described in human monocyte-derived macrophages (HMDMs) in the product information. In vitro, dose-dependent suppression of IL-1β release can be assessed in BMDMs, HMDMs, and human PBMCs while monitoring TNF-α as a specificity and viability-adjacent control. A selective response should reduce IL-1β more strongly than TNF-α; a simultaneous collapse of both signals suggests a problem with cell health, stimulation, or compound handling rather than clean NLRP3 inflammasome inhibition.

This selectivity also creates a valuable comparator framework. AIM2, NLRC4, and NLRP1 responses should not automatically be interpreted as MCC950-sensitive because the compound is not expected to block those inflammasomes. For NLRP3-associated inflammation, the most informative design therefore combines a relevant stimulus, a vehicle control, MCC950 sodium, an orthogonal inflammasome readout, and at least one non-NLRP3 inflammatory output.

Key Innovation from the Reference Study

The study Pathways regulating the release of tissue factor-positive extracellular vesicles and activation of coagulation in endotoxemic mice used a particularly instructive strategy: control mice were compared with Tlr4-deficient, Casp11-deficient, Nlrp3-deficient, and Casp1-deficient animals, while separate wild-type groups received a TLR4 inhibitor or MCC950. The investigators measured blood cells, TNF-α, IL-6, IL-1β, soluble ICAM-1, extracellular-vesicle tissue factor activity, and thrombin-antithrombin complexes at 3 and 8 hours after LPS administration.

The practical innovation was the combination of genetic separation, pharmacological confirmation, timing, and coagulation-focused outputs. TLR4 deficiency reduced TNF-α and IL-6 and lowered extracellular-vesicle tissue factor activity and thrombin-antithrombin complexes at both examined intervals. By contrast, loss or inhibition of the caspase-11/NLRP3 axis reduced tissue factor activity and coagulation activation mainly at the later 8-hour interval, with no corresponding reduction in caspase-1-deficient mice. The authors therefore concluded that TLR4 is the major driver, while caspase-11 and NLRP3 make smaller, delayed contributions.

For assay planning, this means a single late plasma measurement is inadequate. If the question concerns early LPS-driven coagulation, include an upstream TLR4 comparison. If the question concerns delayed inflammasome participation, MCC950 sodium should be paired with IL-1β, extracellular-vesicle tissue factor, and thrombin-antithrombin measurements across a time course. A weak early effect is not necessarily a failed inhibitor experiment; it may reflect the biology resolved by the reference study.

Step-by-step workflow for applied studies

1. Define the pathway question before dosing

Begin by identifying whether the primary endpoint is inflammasome activation, inflammatory cytokine release, extracellular-vesicle tissue factor, or systemic coagulation. Use unstimulated cells or animals, stimulated vehicle controls, and stimulated MCC950 groups. In cell experiments, include viability and morphology checks so that reduced IL-1β is not confused with nonspecific loss of viable macrophages.

For pathway specificity, measure IL-1β together with TNF-α and, where appropriate, IL-6. IL-1β is the most direct pharmacodynamic readout for the intended target in the supplied dossier, whereas TNF-α helps identify effects on upstream inflammatory priming. If testing another inflammasome, interpret a negative MCC950 result as a selectivity control rather than as evidence that the stimulus is inactive.

2. Build a macrophage dose-and-timing matrix

BMDMs are a practical discovery system, while HMDMs and PBMCs provide human-cell context. A useful starting experiment is a small concentration matrix around the reported nanomolar potency, with matched vehicle exposure and a fixed stimulation schedule. Pretreat cells, apply the inflammatory stimulus, and collect supernatants at matched intervals. Preserve a cell lysate or parallel well for viability, protein normalization, or inflammasome-associated measurements.

Do not rely on one endpoint. Pair secreted IL-1β with TNF-α, viability, and—when pyroptosis is relevant—cell-membrane integrity or morphology. The existing resource on MCC950 sodium in viability, proliferation, and pyroptosis assays complements this workflow by emphasizing how cytotoxicity and pyroptotic phenotypes can complicate interpretation. It is especially useful when a strong decrease in cytokine release needs to be distinguished from fewer viable cells.

3. Translate the design into endotoxemia

In a C57BL/6 mouse endotoxemia experiment, administer LPS and MCC950 according to the approved study protocol and the full methods of the selected model. The reference study collected blood at 3 and 8 hours, making those intervals a rational framework for reproducing its temporal comparison. Analyze IL-1β and IL-6 alongside extracellular-vesicle tissue factor activity and thrombin-antithrombin complexes. Soluble ICAM-1 and blood-cell measurements add context for endothelial and hematologic responses.

Interpret pharmacology with appropriate restraint. Because the condensed reference does not provide the exact MCC950 dose or administration schedule, those parameters should be taken from the complete publication methods or independently optimized under institutional approval, not inferred from the product IC₅₀. In vivo exposure, route, formulation, and sampling can alter the apparent contribution of NLRP3.

Protocol Parameters

• Compound storage: keep MCC950 sodium powder at −20 °C, prepare small working aliquots, and use freshly prepared solutions within 1 day rather than retaining them for long-term storage; the product information also reports solubility of at least 124 mg/mL in water, 21.45 mg/mL in DMSO, and 43 mg/mL in ethanol.
• Cell dose finding: as a workflow starting matrix, test 1 nM, 10 nM, and 100 nM MCC950 sodium with a 30–60 minute pretreatment before stimulation; treat these as optimization conditions rather than universal literature doses.
• Vehicle control: keep the final DMSO concentration at or below 0.1% v/v in every well, match it across treatment groups, and incubate the vehicle control for the same 30–60 minute pretreatment interval.
• Culture conditions: maintain macrophages at 37 °C and 5% CO₂, use at least 3 technical wells per condition where plate capacity permits, and collect paired supernatants and viability measurements at the same time point.
• Endotoxemia sampling: for alignment with the reference design, collect blood at 3 hours and 8 hours after intraperitoneal LPS challenge, then analyze IL-1β, IL-6, extracellular-vesicle tissue factor activity, and thrombin-antithrombin complexes in matched samples.

Advanced applications and comparative advantages

Connecting inflammasome biology to coagulation

The reference study makes MCC950 especially useful for inflammatory disease research that extends beyond cytokine measurements. If LPS increases tissue factor-positive extracellular vesicles, a selective NLRP3 intervention can test whether the late coagulation phenotype is partly inflammasome-dependent. The expected effect is not necessarily complete normalization: the study indicates that TLR4 has a larger role, whereas NLRP3 contributes modestly and later. This makes MCC950 more valuable as a mechanistic partitioning tool than as a stand-alone treatment for every endotoxemia endpoint.

Use extracellular-vesicle tissue factor activity as a functional coagulation readout rather than assuming that IL-1β changes predict it perfectly. A useful analysis compares four relationships: stimulus versus vehicle, MCC950 versus stimulated vehicle, early versus late sampling, and cytokine suppression versus tissue-factor suppression. These comparisons can reveal pathway convergence without overclaiming that NLRP3 is the dominant cause of coagulation activation.

Why this cross-domain matters, maturity, and limitations

Inflammasome signaling and coagulation are linked here because the reference directly measured both IL-1β biology and tissue-factor-driven coagulation in the same endotoxemia model. The bridge is therefore experimentally mature enough for hypothesis testing, but it remains model-limited. A reduced plasma IL-1β concentration does not establish that all extracellular-vesicle release is NLRP3-dependent, and an early coagulation signal may remain largely upstream of MCC950-sensitive biology.

The dossier also describes reduced serum IL-1β and IL-6 after LPS challenge and attenuation of disease severity in experimental autoimmune encephalomyelitis, an autoimmune disease model. These findings support extending NLRP3 experiments into inflammatory and autoimmune contexts, but they do not make an endotoxemia result interchangeable with an EAE result. Keep species, tissue, disease stage, and endpoint-specific conclusions separate.

Extending from cells to disease models

For experimental autoimmune encephalomyelitis, use MCC950 as a mechanistic probe alongside clinical scoring and tissue-level inflammatory measurements, rather than treating clinical improvement alone as proof of direct NLRP3 engagement. The translational discussion in MCC950 sodium and translational NLRP3 research extends this concept toward autoimmune disease research; it complements the present coagulation-focused application by emphasizing model selection and pathway specificity.

Troubleshooting and optimization tips

No reduction in IL-1β

First confirm compound identity, preparation, storage, and vehicle matching. Check whether the stimulus actually activated NLRP3 in the chosen cell type by examining a positive IL-1β response in the stimulated vehicle group. If the signal is weak, poor priming, excessive cell loss, or an unsuitable activation sequence may be responsible. If IL-1β rises normally but MCC950 has no effect, expand the concentration and pretreatment matrix while retaining viability controls; do not assume that a single concentration proves target absence.

TNF-α decreases together with IL-1β

The product profile describes selective IL-1β inhibition without impairing TNF-α secretion. A parallel TNF-α decrease therefore warrants investigation of DMSO concentration, compound precipitation, cell density, stimulation quality, and cytotoxicity. Confirm that the cells remain morphologically intact and that an independent inflammatory readout is not broadly suppressed. This check is particularly important in primary human cells, where donor and differentiation variability can be substantial.

Coagulation endpoints change inconsistently

Prioritize timing and sample handling. The reference study observed NLRP3-associated reductions in extracellular-vesicle tissue factor activity and thrombin-antithrombin complexes at 8 hours, but not the same pattern at 3 hours. A study that samples only one early interval can therefore miss the pharmacological contribution. Process plasma consistently, randomize treatment groups across assay plates, and analyze cytokines and coagulation markers from matched animals whenever possible.

Unexpected activity in a non-NLRP3 assay

Use AIM2, NLRC4, or NLRP1-related experiments as selectivity controls, but verify that the stimulus and readout are appropriate for that inflammasome. MCC950 is expected to be selective rather than pan-inflammasome. Apparent inhibition may instead reflect changes in cell viability, stimulus uptake, assay interference, or an indirect effect on shared downstream biology.

Future outlook

The most productive next step is not simply higher dosing, but better temporal and mechanistic resolution. Combining early and late blood collection with IL-1β, TNF-α, IL-6, extracellular-vesicle tissue factor, and thrombin-antithrombin measurements can define where NLRP3 sits within an endotoxemia response. Parallel BMDM, HMDM, PBMC, and disease-model experiments can then test which observations are conserved across systems. The evidence reviewed here supports MCC950 sodium as a precise pathway-dissection reagent: powerful for identifying NLRP3-associated contributions, yet most informative when interpreted alongside upstream controls, non-NLRP3 comparators, viability data, and model-specific limitations.